March 11, 2022 5:21pm

Ends a red” week with a volatile session without any trust in going long over weekend

Pre-open indications: 6 Hits, 3 Miss and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The multiple metrics and Bottom Line say it all succinctly … just the facts

The week in review …

 

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -229.88 points (-0.69%); the S&P closed DOWN -55.21 points (-1.30%) while the Nasdaq closed DOWN -286.15 points (-2.15%)

 

Henry’omics:

The war in Ukraine, now in its third week, and the prospect of central banks tightening monetary policy to tame inflation just as the global economy begins to slow has sent financial markets swinging wildly up and -- mostly -- down. <Reuters>.

The S&P 500 fell, the Dow tripped 35 points and the Nasdaq dived about 1%. The Dow is headed for its fifth (5th) straight week of losses. The S&P and Nasdaq are heading for their second (2nd) straight week of losses.

Week to date, the Dow is down about 0.9%, the S&P is down roughly 1.5%, and the Nasdaq is off by 1.6% this week.

News that consumer confidence sunk even lower this morning as household fears about inflation intensify have ramped up worries. the University of Michigan consumer sentiment index sunk to 59.7 in March, down from 62.8 in February. This marks the weakest print since September 2011.

 

This a.m.’s post, RegMed Investors’ (RMi) pre-open: “dramatic market and sector moves are still questionable.  Ceasefire talks between Russia and Ukraine could be helping markets to gain traction; although Thursday’s aftermarket was extremely weak, an indication” …  https://www.regmedinvestors.com/articles/12337

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Friday opened negative at 11 up/26 downs and 1 flat, stayed negative at the mid-day at 7/30 and 1 flat, ending with a negative close of 6/31 and 1 flat;
  • Thursday opened negative at 3 up/35 downs, stayed negative at the mid-day at 9/29, ending with a negative close of 6/26;
  • Wednesday opened positive at 36 up/0 downs, 2 flats, stayed positive at the mid-day at 35/3, ending with a positive close of 35/3;
  • Tuesday opened negative at 6 up/21 downs and1 flat, strayed positive at the mid-day at 33/3 and 2 flats, ending with a positive close of 24/12 and 2 flat;
  • Monday opened negative at 8 up/27 downs, 2 flats, stayed negative at the mid-day at 14/24, ending with a negative close of 11/26 and 2 flats;

 

Pre-open Indications: 6 Hits < Cellectis SA (CLLS +$0.195), CRISPR Therapeutics (CRSP +$0.05), Intellia Therapeutics (NTLA -$1.91), Ionis Pharmaceuticals (IONS -$0.78), Voyager Therapeutics (VYGR -$0.29), Sangamo Therapeutics (SGMO -$0.12)> 3 Miss <Agenus (AGEN -$0.11), Caribou Therapeutics (CRBU -$0.36), Intellia Therapeutics (NTLA -$1.91) > and 1 Pimp/Pump/Promote <Biostage (BSTG +$0.39),

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  …

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Friday with 1,602 shares trading up +$0.39 after Thursday -$0.63 with 488 shares traded after Wednesday -$0.26 with 1,225 shares traded, Tuesday flat with 1,130 shares traded, Monday’s close +$0.29 with 399 shares traded, Friday closing down -$0.44 with 1,303 shares traded

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • By use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering
  • BSTG is NOT going ANYWHERE without a cash inflow.

 

Key Metrics:

  • Friday - Sector volume was LOW with 2 of the 6-upside having higher than the 3-month average volume with LOW volume of 3 of 31-downside having higher than the 3-month average volume;
  • Thursday - Sector volume was LOW with 1 of the 12-upside having higher than the 3-month average volume with LOW volume of 2 of 26-downside having higher than the 3-month average volume;
  • Wednesday - Sector volume was LOW with 11 of the 35-upside having higher than the 3-month average volume with LOW volume of 0 of 3-downside having higher than the 3-month average volume;
  • Tuesday - Sector volume was LOW with 6 of the 24-upside having higher than the 3-month average volume with LOW volume of 2 of 12-downside having higher than the 3-month average volume;
  • Monday - Sector volume was LOW with 2 of the 11-upside having higher than the 3-month average volume with LOW volume of 5 of 26-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed down -1.91% and XBI closed down -3.83%
  • Thursday, the IBB closed down -1.01% and XBI closed down -0.52%
  • Wednesday, the IBB closed up +3.27% and XBI closed up +4.89%
  • Tuesday, the IBB closed down -0.25% and XBI closed up +0.67%
  • Monday the IBB closed down -0.17 and the XBI closed up +0.13%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +0.52 points or +1.52% at 30.75
  • Thursday was down -2.22 points or -6.84% at 30.23
  • Wednesday was down -2.68 points or -7.63% at 32.45
  • Tuesday was down -0.96 points or -2.63% at 35.45
  • Monday was up +4.47 points or +13.98% at 36.45

 

Jumping with share pricing momentum (6 of 6):

  • Biostage (BSTG +$0.39 after Thursday’s -$0.63 and Wednesday’s -$0.26),
  • Solid Biosciences (SLDB +$0.288),
  • Cellectis SA (CLLS +$0.20 after Thursday’s +$0.06),
  • Bellicum Pharmaceuticals (BLCM +$0.11 after Thursday’s +$0.07),
  • Verastem (VSTM +$0.10),
  • Pluristem (PSTI +$0.03),

Hammered in today’s market (10 of 31):

  • Alnylam Pharmaceuticals (ALNY -$5.60 after Thursday’s -$1.67),
  • Beam Therapeutics (BEAM -$4.81 after Thursday’s +$0.61 Wednesday’s +$2.64 and Tuesday’s -$0.34),
  • Intellia Therapeutics (NTLA -$4.62),
  • Vericel (VCEL -$2.40 after Thursday’s -$1.41, Wednesday’s +$1.23, Tuesday’s -$1.11 and Monday’s -$1.76),
  • Ultragenyx (RARE -$2.11),
  • Fate Therapeutics (FATE -$1.93 after Thursday’s +$0.07, Wednesday’s +$2.64, Tuesday’s +$0.91 and Monday’s -$0.61)
  • Regenxbio (RGNX -$1.46 after Thursday’s +$0.41 and Wednesday’s -$0.08),
  • Editas Medicine (EDIT -$1.17 after Thursday’s -$0.40),
  • Sage Therapeutics (SAGE -$1.08 after Thursday’s -$0.62),
  • BioLife Solutions (BLFS -$1.02 after Thursday’s -$0.45, Wednesday’s +$1.12, Tuesday’s -$0.36 and Monday’s -$0.36),),

Closing Flat:  

  • ReNeuron (RENE.L),

 

March, Q1/2022:

  • Friday closed negative with 6 incliners and 31 decliners and 1 flat
  • Thursday closed negative with 12 incliners and 36 decliners
  • Wednesday closed positive with 35 incliners, 3 decliners
  • Tuesday closed positive with 24 incliners, 12 decliners and 2 flats
  • Monday closed negative with 11 incliners, 26 decliners and 1 flat (PGEN)

 

 

The BOTTOM LINE: Hell of a week!

But after another bruising week and cell and gene therapy sector equities pricing down from Wednesday’s high assisted by Tuesday’s appreciation, traders might be look for reasons to buy into a few risky stocks.

Uncertainty definitely surrounded the cell and gene therapy sector …

The sector was mostly lower, as algorithms stripped most equities of any upside (the downfall range was -0.29% to -5.97% while the upside placed its forward motion +0.78% to +9.97%.

·         Ascending to the top of the sector’s appreciation lost was Biostage +$0.39 or +9.97% (but, that is “pimp/pumped/promoted by non-U.S. investors flowed),  Cellectis SA (CLLS), Verastem (VSTM), Pluristem (PSTI) and Bellicum Pharmaceuticals (BLCM) in today’s upside

·         Alnylam Pharmaceuticals (ALNY), Intellia Therapeutics (NTLA) and Beam Therapeutics (BEAM) led the losers

I don't think we've seen the bottom yet. And I'd like to be more optimistic, but the reason I say this is the algorithms are always lurking for profiting.

The cell and gene therapy sector’s volume remain LOW.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are still “gamy” than even I thought.

Earnings’ reporting coming:

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.